Skip to main content
Erschienen in: Die Urologie 12/2021

30.11.2021 | Computertomografie | Leitthema

Bildgebung oligometastasierter Tumoren des Harntraktes

verfasst von: S. A. Koerber, C. A. Fink, K. Dendl, D. Schmitt, G. Niegisch, E. Mamlins, Univ.-Prof. Dr. F. L. Giesel

Erschienen in: Die Urologie | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Klinische Studien zeigen für die Lokaltherapie von Primarius und Metastasen urologischer Tumoren im metastasierten Stadium Vorteile gegenüber einer alleinigen Systemtherapie und definieren ein potenziell kuratives oligometastasiertes Stadium.

Fragestellung

Bildgebungsmodalitäten zur sensitiven lokalen und systemischen Diagnostik von urologischen Tumoren im oligometastasierten Stadium werden verglichen.

Material und Methode

Es wird eine Übersicht über und Zusammenfassung von vergleichenden Studien zu Gütekriterien unterschiedlicher Bildgebungsmodalitäten zusammengestellt.

Ergebnisse

Abhängig vom betroffenen Organsystem und der Tumorentität bestimmen konventionelle Bildgebungsmodalitäten wie Computertomographie (CT) und Knochenszintigraphie weiterhin die Praxis in Deutschland. Die Hybridbildgebung (PET [Positronenemissionstomographie]/CT) konnte sich in den vergangenen Jahren aufgrund überlegener Gütekriterien in der Onkologie und insbesondere beim Prostatakarzinom durch neue Liganden (PSMA, „prostate-specific membrane antigen“) etablieren. Bei allen Entitäten ist die Entwicklung neuer Bildgebungsliganden (z. B. FAP-Liganden [„fibroblast activated protein“]) und deren klinische Anwendung Gegenstand aktueller Forschung.

Schlussfolgerungen

Die Entwicklung sensitiverer Bildgebungen durch neue Liganden besonders in der Nuklearmedizin legt die Grundlage zur exakten Definition oligometastasierter Stadien. Hierdurch werden Lokaltherapien möglich, die eine Progression oder Systemtherapie hinauszögern, aber auch kurative Therapieoptionen durch Behandlung sämtlicher Tumorlokalisationen ermöglichen können.
Literatur
1.
Zurück zum Zitat Barnes B, Kraywinkel K, Nowossadeck E et al (2016) Bericht zum Krebsgeschehen in Deutschland 2016 Barnes B, Kraywinkel K, Nowossadeck E et al (2016) Bericht zum Krebsgeschehen in Deutschland 2016
2.
Zurück zum Zitat Krebsgesellschaft Krebshäufigkeit – die aktuellen Zahlen | DKG. Krebsgesellschaft Krebshäufigkeit – die aktuellen Zahlen | DKG.
3.
Zurück zum Zitat Gekid GEKID-Atlas – Tabellenabfrage. Gekid GEKID-Atlas – Tabellenabfrage.
4.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL. In: Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL. In:
5.
Zurück zum Zitat Palma DA, Salama JK, Lo SS et al (2014) The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 11:549–557PubMed Palma DA, Salama JK, Lo SS et al (2014) The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 11:549–557PubMed
7.
Zurück zum Zitat Milano MT, Biswas T, Ii SCB et al (2021) Oligometastases: history of a hypothesis. Ann Palliat Med 10:5923–5930PubMed Milano MT, Biswas T, Ii SCB et al (2021) Oligometastases: history of a hypothesis. Ann Palliat Med 10:5923–5930PubMed
8.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2020) Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 2.0, 2020, AWMF Registernummer: 043/017OL. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2020) Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 2.0, 2020, AWMF Registernummer: 043/017OL.
9.
Zurück zum Zitat Duden oligo- | Rechtschreibung, Bedeutung, Definition, Herkunft. Duden oligo- | Rechtschreibung, Bedeutung, Definition, Herkunft.
10.
Zurück zum Zitat Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10PubMed Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10PubMed
11.
Zurück zum Zitat Kaneda H, Saito Y (2015) Oligometastases: defined by prognosis and evaluated by cure. Cancer Treat Commun 3:1–6 Kaneda H, Saito Y (2015) Oligometastases: defined by prognosis and evaluated by cure. Cancer Treat Commun 3:1–6
12.
Zurück zum Zitat Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058PubMed Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058PubMed
13.
Zurück zum Zitat Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38:2830–2838PubMedPubMedCentral Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38:2830–2838PubMedPubMedCentral
14.
Zurück zum Zitat Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353–2366PubMedPubMedCentral Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353–2366PubMedPubMedCentral
15.
Zurück zum Zitat Kosmin M, Padhani AR, Gogbashian A et al (2020) Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology 297:622–629PubMed Kosmin M, Padhani AR, Gogbashian A et al (2020) Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology 297:622–629PubMed
16.
Zurück zum Zitat Tosoian JJ, Gorin MA, Ross AE et al (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14:15–25PubMed Tosoian JJ, Gorin MA, Ross AE et al (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14:15–25PubMed
17.
Zurück zum Zitat Yang HL, Liu T, Wang XM et al (2011) Diagnosis of bone metastases: a meta-analysis comparing (1)(8)FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617PubMed Yang HL, Liu T, Wang XM et al (2011) Diagnosis of bone metastases: a meta-analysis comparing (1)(8)FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604–2617PubMed
18.
Zurück zum Zitat Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208–1216PubMed Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208–1216PubMed
19.
Zurück zum Zitat Malaspina S, Anttinen M, Taimen P et al (2021) Prospective comparison of (18)F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 48:2951–2959PubMedPubMedCentral Malaspina S, Anttinen M, Taimen P et al (2021) Prospective comparison of (18)F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 48:2951–2959PubMedPubMedCentral
20.
Zurück zum Zitat Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395PubMed Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395PubMed
21.
Zurück zum Zitat Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287PubMed Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287PubMed
22.
Zurück zum Zitat Bonekamp D, Jacobs MA, El-Khouli R et al (2011) Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics 31:677–703PubMedPubMedCentral Bonekamp D, Jacobs MA, El-Khouli R et al (2011) Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics 31:677–703PubMedPubMedCentral
23.
Zurück zum Zitat Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340–351PubMed Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340–351PubMed
24.
Zurück zum Zitat Barnes A, Alonzi R, Blackledge M et al (2018) UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. Br J Radiol 91:20170577PubMed Barnes A, Alonzi R, Blackledge M et al (2018) UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. Br J Radiol 91:20170577PubMed
25.
Zurück zum Zitat Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of Multiorgan involvement in advanced prostate cancer. Eur Urol 71:81–92PubMedPubMedCentral Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of Multiorgan involvement in advanced prostate cancer. Eur Urol 71:81–92PubMedPubMedCentral
26.
Zurück zum Zitat Fanti S, Goffin K, Hadaschik BA et al (2021) Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48:469–476PubMed Fanti S, Goffin K, Hadaschik BA et al (2021) Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48:469–476PubMed
27.
Zurück zum Zitat Linton KD, Catto JW (2012) Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost? Eur Urol 62:76–77PubMed Linton KD, Catto JW (2012) Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost? Eur Urol 62:76–77PubMed
28.
Zurück zum Zitat Schoder H, Herrmann K, Gonen M et al (2005) 2‑[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11:4761–4769PubMed Schoder H, Herrmann K, Gonen M et al (2005) 2‑[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11:4761–4769PubMed
29.
Zurück zum Zitat Fanti S, Minozzi S, Castellucci P et al (2016) PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 43:55–69PubMed Fanti S, Minozzi S, Castellucci P et al (2016) PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 43:55–69PubMed
30.
Zurück zum Zitat Giesel FL, Will L, Lawal I et al (2018) Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study. J Nucl Med 59:1076–1080PubMed Giesel FL, Will L, Lawal I et al (2018) Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study. J Nucl Med 59:1076–1080PubMed
31.
Zurück zum Zitat Rahbar K, Weckesser M, Ahmadzadehfar H et al (2018) Advantage of (18)F-PSMA-1007 over (68)Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion. Eur J Nucl Med Mol Imaging 45:1076–1077PubMed Rahbar K, Weckesser M, Ahmadzadehfar H et al (2018) Advantage of (18)F-PSMA-1007 over (68)Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion. Eur J Nucl Med Mol Imaging 45:1076–1077PubMed
33.
Zurück zum Zitat Dyrberg E, Hendel HW, Huynh THV et al (2019) (68)Ga-PSMA-PET/CT in comparison with (18)F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol 29:1221–1230PubMed Dyrberg E, Hendel HW, Huynh THV et al (2019) (68)Ga-PSMA-PET/CT in comparison with (18)F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol 29:1221–1230PubMed
34.
Zurück zum Zitat Zacho HD, Nielsen JB, Afshar-Oromieh A et al (2018) Prospective comparison of (68)Ga-PSMA PET/CT, (18)F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 45:1884–1897PubMed Zacho HD, Nielsen JB, Afshar-Oromieh A et al (2018) Prospective comparison of (68)Ga-PSMA PET/CT, (18)F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 45:1884–1897PubMed
35.
Zurück zum Zitat Guberina N, Hetkamp P, Ruebben H et al (2020) Whole-body integrated [(68)ga]PSMA-11-PET/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET/CT as the standard of reference. Mol Imaging Biol 22:788–796PubMed Guberina N, Hetkamp P, Ruebben H et al (2020) Whole-body integrated [(68)ga]PSMA-11-PET/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET/CT as the standard of reference. Mol Imaging Biol 22:788–796PubMed
36.
Zurück zum Zitat Scosyrev E, Messing J, Noyes K et al (2012) Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol 30:126–132PubMed Scosyrev E, Messing J, Noyes K et al (2012) Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol 30:126–132PubMed
37.
Zurück zum Zitat Murphy DG, Sweeney CJ, Tombal B (2017) “Gotta catch ’em all”, or do we? Pokemet approach to metastatic prostate cancer. Eur Urol 72:1–3PubMed Murphy DG, Sweeney CJ, Tombal B (2017) “Gotta catch ’em all”, or do we? Pokemet approach to metastatic prostate cancer. Eur Urol 72:1–3PubMed
38.
Zurück zum Zitat Campbell SC, Uzzo RG, Karam JA et al (2021) Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part II. J Urol 206:209–218PubMed Campbell SC, Uzzo RG, Karam JA et al (2021) Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part II. J Urol 206:209–218PubMed
39.
Zurück zum Zitat Sohaib SA, Cook G, Allen SD et al (2009) Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br J Radiol 82:632–639PubMed Sohaib SA, Cook G, Allen SD et al (2009) Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br J Radiol 82:632–639PubMed
40.
Zurück zum Zitat Staudenherz A, Steiner B, Puig S et al (1999) Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer 85:153–155PubMed Staudenherz A, Steiner B, Puig S et al (1999) Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer 85:153–155PubMed
41.
Zurück zum Zitat Gerety EL, Lawrence EM, Wason J et al (2015) Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol 26:2113–2118PubMedPubMedCentral Gerety EL, Lawrence EM, Wason J et al (2015) Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol 26:2113–2118PubMedPubMedCentral
42.
Zurück zum Zitat Jee HB, Park MJ, Lee HS et al (2015) Is non-contrast CT adequate for the evaluation of hepatic metastasis in patients who cannot receive Iodinated contrast media? PLoS ONE 10:e134133PubMedPubMedCentral Jee HB, Park MJ, Lee HS et al (2015) Is non-contrast CT adequate for the evaluation of hepatic metastasis in patients who cannot receive Iodinated contrast media? PLoS ONE 10:e134133PubMedPubMedCentral
43.
Zurück zum Zitat Chang A, Finelli A, Berns JS et al (2014) Chronic kidney disease in patients with renal cell carcinoma. Adv Chronic Kidney Dis 21:91–95PubMed Chang A, Finelli A, Berns JS et al (2014) Chronic kidney disease in patients with renal cell carcinoma. Adv Chronic Kidney Dis 21:91–95PubMed
44.
Zurück zum Zitat Davenport MS, Khalatbari S, Cohan RH et al (2013) Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 268:719–728PubMed Davenport MS, Khalatbari S, Cohan RH et al (2013) Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 268:719–728PubMed
45.
Zurück zum Zitat Media ACODaC (2021) ACR manual on contrast media Media ACODaC (2021) ACR manual on contrast media
46.
Zurück zum Zitat Karivedu V, Jain AL, Eluvathingal TJ et al (2019) Role of positron emission tomography imaging in metabolically active renal cell carcinoma. Curr Urol Rep 20:56PubMed Karivedu V, Jain AL, Eluvathingal TJ et al (2019) Role of positron emission tomography imaging in metabolically active renal cell carcinoma. Curr Urol Rep 20:56PubMed
47.
Zurück zum Zitat Aide N, Cappele O, Bottet P et al (2003) Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30:1236–1245PubMed Aide N, Cappele O, Bottet P et al (2003) Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30:1236–1245PubMed
48.
49.
Zurück zum Zitat Namura K, Minamimoto R, Yao M et al (2010) Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 10:667PubMedPubMedCentral Namura K, Minamimoto R, Yao M et al (2010) Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 10:667PubMedPubMedCentral
50.
Zurück zum Zitat Ferda J, Ferdova E, Hora M et al (2013) 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res 33:2665–2672PubMed Ferda J, Ferdova E, Hora M et al (2013) 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res 33:2665–2672PubMed
51.
Zurück zum Zitat Nakaigawa N, Kondo K, Tateishi U et al (2016) FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer 16:67PubMedPubMedCentral Nakaigawa N, Kondo K, Tateishi U et al (2016) FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer 16:67PubMedPubMedCentral
52.
Zurück zum Zitat Lee H, Hwang KH, Kim SG et al (2014) Can initial (18)F-FDG PET-CT imaging give information on metastasis in patients with primary renal cell carcinoma? Nucl Med Mol Imaging 48:144–152PubMed Lee H, Hwang KH, Kim SG et al (2014) Can initial (18)F-FDG PET-CT imaging give information on metastasis in patients with primary renal cell carcinoma? Nucl Med Mol Imaging 48:144–152PubMed
53.
Zurück zum Zitat Baccala A, Sercia L, Li J et al (2007) Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70:385–390PubMed Baccala A, Sercia L, Li J et al (2007) Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70:385–390PubMed
54.
Zurück zum Zitat Rowe SP, Gorin MA, Hammers HJ et al (2015) Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. Ann Nucl Med 29:877–882PubMedPubMedCentral Rowe SP, Gorin MA, Hammers HJ et al (2015) Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. Ann Nucl Med 29:877–882PubMedPubMedCentral
55.
Zurück zum Zitat Has Simsek D, Civan C, Erdem S et al (2021) Complementary role of 68ga-prostate-specific membrane antigen and 18F-FDG PET/CT for evaluation of metastases and treatment response in renal cell carcinoma. Clin Nucl Med 46:579–581PubMed Has Simsek D, Civan C, Erdem S et al (2021) Complementary role of 68ga-prostate-specific membrane antigen and 18F-FDG PET/CT for evaluation of metastases and treatment response in renal cell carcinoma. Clin Nucl Med 46:579–581PubMed
56.
Zurück zum Zitat Verhoeff SR, Van Es SC, Boon E et al (2019) Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging 46:1931–1939PubMedPubMedCentral Verhoeff SR, Van Es SC, Boon E et al (2019) Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging 46:1931–1939PubMedPubMedCentral
57.
Zurück zum Zitat Network NCC NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Kidney Cancer Version 1.2022. Network NCC NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Kidney Cancer Version 1.2022.
58.
Zurück zum Zitat Zhang Y, Schoenhals J, Christie A et al (2019) Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 105:367–375PubMedPubMedCentral Zhang Y, Schoenhals J, Christie A et al (2019) Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 105:367–375PubMedPubMedCentral
59.
Zurück zum Zitat All S, Garant A, Hannan R (2021) Stereotactic Ablative Radiation (SAbR) for oligometastatic RCC. Semin Radiat Oncol 31:227–234PubMed All S, Garant A, Hannan R (2021) Stereotactic Ablative Radiation (SAbR) for oligometastatic RCC. Semin Radiat Oncol 31:227–234PubMed
60.
Zurück zum Zitat University of Texas Southwestern Medical C (2023) SAbR for Oligometastatic renal cell carcinoma University of Texas Southwestern Medical C (2023) SAbR for Oligometastatic renal cell carcinoma
61.
Zurück zum Zitat Crozier J, Papa N, Perera M et al (2019) Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World J Urol 37:667–690PubMed Crozier J, Papa N, Perera M et al (2019) Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World J Urol 37:667–690PubMed
62.
Zurück zum Zitat Voskuilen CS, Schweitzer D, Jensen JB et al (2020) Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract Urothelial carcinoma. Eur Urol Oncol 3:73–79PubMed Voskuilen CS, Schweitzer D, Jensen JB et al (2020) Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract Urothelial carcinoma. Eur Urol Oncol 3:73–79PubMed
63.
Zurück zum Zitat Lu YY, Chen JH, Liang JA et al (2012) Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 81:2411–2416PubMed Lu YY, Chen JH, Liang JA et al (2012) Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 81:2411–2416PubMed
64.
Zurück zum Zitat Kratochwil C, Flechsig P, Lindner T et al (2019) (68)ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60:801–805PubMedPubMedCentral Kratochwil C, Flechsig P, Lindner T et al (2019) (68)ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60:801–805PubMedPubMedCentral
66.
Zurück zum Zitat Nieuwenhuijzen JA, Bex A, Meinhardt W et al (2005) Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 174:80–85PubMed Nieuwenhuijzen JA, Bex A, Meinhardt W et al (2005) Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 174:80–85PubMed
67.
Zurück zum Zitat Moschini M, Xylinas E, Zamboni S et al (2020) Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database. Eur Urol Oncol 3:94–101PubMed Moschini M, Xylinas E, Zamboni S et al (2020) Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database. Eur Urol Oncol 3:94–101PubMed
Metadaten
Titel
Bildgebung oligometastasierter Tumoren des Harntraktes
verfasst von
S. A. Koerber
C. A. Fink
K. Dendl
D. Schmitt
G. Niegisch
E. Mamlins
Univ.-Prof. Dr. F. L. Giesel
Publikationsdatum
30.11.2021
Verlag
Springer Medizin
Erschienen in
Die Urologie / Ausgabe 12/2021
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-021-01708-0

Weitere Artikel der Ausgabe 12/2021

Die Urologie 12/2021 Zur Ausgabe

Berufspolitik BvDU

Berufspolitik BvDU

Aktuelles aus der DGU-Pressestelle

Aktuelles aus der DGU-Pressestelle

Passend zum Thema

ANZEIGE

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

ANZEIGE

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

ANZEIGE

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

LEO Pharma GmbH